Ole Hudowenz,Jan Vorwerk,Cyrus Khandanpour et al.
Ole Hudowenz et al.
Not available.
Immune mediated marrow failure in very young children: horse ATG once again out of the magician's hat [0.03%]
Marc Bierings,Kirsten Thus
Marc Bierings
Not available.
The evolution of the complete blood count: have we gone too far? Perhaps we have. Comment on: "The evolution of the complete blood count: have we gone too far?" [0.03%]
Daniel Mazza Matos
Daniel Mazza Matos
Not available.
SIRT3 deSUMOylation sustains hematopoietic stem cell activities under stressful conditions via the DHX58-IRF7 axis [0.03%]
Xiaoxiao He,Jing Yu,Yilu Xu et al.
Xiaoxiao He et al.
Hematopoietic stem cells (HSCs) sustain physiological hematopoiesis by generating all hematopoietic cells. However, the connection between HSC stemness/activities and organismal lifespan, especially under stress, remains incompletely unders...
Fengbiao Zhou
Fengbiao Zhou
Not available.
Myeloid blast phase of chronic myeloid leukemia with co-occurring t(11;12)(p15;q13)/ NUP98:: HOXC12: a novel NUP98 fusion partner [0.03%]
Azeem Khan,Jie Xu,Beenu Thakral et al.
Azeem Khan et al.
Not available.
Corinna Lutterbeck,Derrick Kaufman,Christopher R Bolen et al.
Corinna Lutterbeck et al.
Follicular lymphoma (FL) is an indolent disease with favorable outcome in patients with symptomatic disease treated with anti-CD20 based immunochemotherapy. However, a subset of patients experiencing progression within 24 months (POD24) hav...
Karney Lahad,Ofrat Beyar-Katz,Mohamad Dallasheh et al.
Karney Lahad et al.
Not available.
Favorable safety and efficacy profiles of α-1-antitrypsin in steroid- and ruxolitinib-refractory acute graft- versus-host disease of the gastrointestinal tract: a retrospective, single center study [0.03%]
Dana Yehudai-Ofir,Hazim Khatib,Ofrat Beyar-Katz et al.
Dana Yehudai-Ofir et al.
Not available.
Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab [0.03%]
Guido Lancman,Dahniel Sastow,Minira Aslanova et al.
Guido Lancman et al.
Daratumumab is an anti-CD38 monoclonal antibody that has shown clinical benefit in both relapsed/refractory as well as newly diagnosed multiple myeloma (MM). Although daratumumab is very well-tolerated, randomized clinical trial data have c...